Maria De Santis

9.2k total citations · 1 hit paper
25 papers, 1.4k citations indexed

About

Maria De Santis is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Maria De Santis has authored 25 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pulmonary and Respiratory Medicine, 11 papers in Oncology and 7 papers in Cancer Research. Recurrent topics in Maria De Santis's work include Prostate Cancer Treatment and Research (22 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Maria De Santis is often cited by papers focused on Prostate Cancer Treatment and Research (22 papers), Prostate Cancer Diagnosis and Treatment (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Maria De Santis collaborates with scholars based in Austria, Germany and France. Maria De Santis's co-authors include Nicolas Mottet, Philip Cornford, Henk G. van der Poel, Olivier Rouvière, Malcolm D. Mason, Erik Briers, Thomas Lam, Ann Henry, Steven Joniau and M. Bolla and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and International Journal of Cancer.

In The Last Decade

Maria De Santis

20 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

2016 1.1k citations Philip Cornford, Joaquim Bellmunt et al. European Urology profile →

Peers

Countries citing papers authored by Maria De Santis

Since Specialization

Citations

This map shows the geographic impact of Maria De Santis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Maria De Santis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Maria De Santis more than expected).

Fields of papers citing papers by Maria De Santis

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Maria De Santis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Maria De Santis. The network helps show where Maria De Santis may publish in the future.

Co-authorship network of co-authors of Maria De Santis

This figure shows the co-authorship network connecting the top 25 collaborators of Maria De Santis. A scholar is included among the top collaborators of Maria De Santis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Maria De Santis. Maria De Santis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Patient-reported Outcomes in KEYLYNK-010: Pembrolizumab Plus Olaparib Versus Abiraterone or Enzalutamide for Participants with Biomarker-unselected, Previously Treated Metastatic Castration-resistant Prostate Cancer 2025 ·European Urology Oncology ·Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Ray McDermott, (unknown), Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, (unknown), Sameer R. Ghate, Yi Cui, Christian Hosius, Evan Y. Yu	1
2	Androgen Receptor Pathway Inhibitor Monotherapy in Prostate Cancer: Safety, Oncologic Outcomes, and Quality of Life—A Systematic Review and Meta-analysis 2025 ·European Urology Focus ·Tamás Fazekas, Marcin Miszczyk, (unknown), Tamás Kói, Fabio Zattoni, (unknown), Takafumi Yanagisawa, Akihiro Matsukawa, Tibor Szarvas, (unknown), Juan Gómez Rivas, Axel S. Merseburger, Maria De Santis, Steven Joniau, (unknown), (unknown), Péter Nyírády, (unknown), Shahrokh F. Shariat, Paweł Rajwa	2
3	AI-driven body composition monitoring and its prognostic role in mCRPC undergoing lutetium-177 PSMA radioligand therapy: insights from a retrospective single-center analysis 2025 ·EJNMMI Research ·(unknown), Julian M.M. Rogasch, (unknown), Imke Schatka, Christoph Wetz, Christian Furth, (unknown), Maria De Santis, (unknown), (unknown), Dominik Geisel, Holger Amthauer, Nick Lasse Beetz	0
4	Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Guérin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data 2025 ·World Journal of Urology ·Jaime Luna, Eveline Otte im Kampe, (unknown), Moritz Lehne, (unknown), (unknown), (unknown), (unknown), Agnes Kisser, Nils Kroeger, Maria De Santis	0
5	Patient-reported Outcomes in KEYNOTE-921: Pembrolizumab with Docetaxel and Prednisone for Patients with Metastatic Castration-resistant Prostate Cancer 2025 ·European Urology Oncology ·Nobuaki Matsubara, Daniel P. Petrylak, Raffaele Ratta, Ernesto Korbenfeld, Rustem Gafanov, Loı̈c Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries M. Bergman, Paweł Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell K. Pachynski, (unknown), Sameer R. Ghate, (unknown), Charles Schloss, Karim Fizazi	1
6	Add-on Rituximab for Primary Heart Involvement Associated with Systemic Sclerosis: A Step Forward in the Tailored Treatment of Myocarditis? 2024 ·European Journal of Heart Failure ·Maria De Santis, (unknown), Francesca Motta, (unknown), Lorenzo Monti, Federica Catapano, (unknown), Carlo Selmi	2
7	Feasibility of Indirect Treatment Comparisons Between Niraparib Plus Abiraterone Acetate and Other First-Line Poly ADP-Ribose Polymerase Inhibitor Treatment Regimens for Patients with BRCA1/2 Mutation-Positive Metastatic Castration-Resistant Prostate Cancer 2024 ·Advances in Therapy ·Maria De Santis, (unknown), Paul Robinson, (unknown), (unknown), Suzy Van Sanden, Mahmoud Hashim, Marco Trevisan, Caitlin Daly, (unknown), (unknown), (unknown), Bart Heeg, Elena Verzoni	0
8	Patient-reported outcomes (PROs) in KEYNOTE-921: Pembrolizumab (pembro) plus docetaxel for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). 2023 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Korbenfeld, Rustem Gafanov, Loı̈c Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries M. Bergman, Paweł Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell K. Pachynski, (unknown), Sameer R. Ghate, (unknown), Charles Schloss, Karim Fizazi	1
9	Pembrolizumab plus docetaxel for patients with metastatic castration-resistant prostate cancer (mCRPC): Randomized, double-blind, phase 3 KEYNOTE-921 study. 2023 ·Journal of Clinical Oncology ·Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, Ernesto Korbenfeld, Rustem Gafanov, Loı̈c Mourey, Tilman Todenhöfer, Howard Gurney, Gero Kramer, Andries M. Bergman, Paweł Zalewski, Maria De Santis, Andrew J. Armstrong, Winald R. Gerritsen, Russell K. Pachynski, Seok‐Soo Byun, (unknown), Charles Schloss, Christian Poehlein, Karim Fizazi	24
10	Patient-reported outcomes (PROs) in KEYLYNK-010: Pembrolizumab (pembro) plus olaparib (ola) vs abiraterone acetate (abi) or enzalutamide (enza) for patients (pts) with previously treated metastatic castration-resistant prostate cancer (mCRPC). 2023 ·Journal of Clinical Oncology ·Niven Mehra, Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Ray McDermott, (unknown), Peter C.C. Fong, Richard Greil, Maria De Santis, Patricio Yañez, Eric Yi‐Hsiu Huang, Stephen Begbie, Felipe Rey, Gero Kramer, Hiroyoshi Suzuki, (unknown), Sameer R. Ghate, Yi Cui, Jeri Kim, Evan Y. Yu	3
11	Precision Oncology for Metastatic Prostate Cancer: Translation into Practice 2020 ·European Urology ·Maria De Santis, Nicolas Mottet, Philip Cornford, Silke Gillessen	3
12	Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with 177Lu-labeled prostate-specific membrane antigen 2020 ·Annals of Nuclear Medicine ·Kai Huang, Imke Schatka, Julian M.M. Rogasch, Randall L. Lindquist, Maria De Santis, (unknown), Piotr Radojewski, Winfried Brenner, Holger Amthauer	6
13	Therapie des metastasierten Prostatakarzinoms im Wandel – neue Daten und offene Fragen 2019 ·Der Urologe ·Peter Albers, Martin Bögemann, S. Machtens, Axel S. Merseburger, Martin Schostak, Thomas Steuber, Christian Wülfing, Maria De Santis	0
14	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018 2018 ·European Urology ·Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, Philip Cornford, (unknown), Ann Henry, Thomas Lam, Malcolm D. Mason, Olivier Rouvière, Maria De Santis, Peter-Paul Willemse, Hendrik Van Poppel, Nicolas Mottet	124
15	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer breakdown → 2016 ·European Urology ·Philip Cornford, Joaquim Bellmunt, M. Bolla, Erik Briers, Maria De Santis, Tobias Gross, Ann Henry, Steven Joniau, Thomas Lam, Malcolm D. Mason, Henk G. van der Poel, Theodorus van der Kwast, Olivier Rouvière, Thomas Wiegel, Nicolas Mottet	1103
16	Practical Guidance on the Role of Corticosteroids in the Treatment of Metastatic Castration-resistant Prostate Cancer 2016 ·Urology ·Maria De Santis, Fred Saad	23
17	Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy 2015 ·Cancer Immunology Immunotherapy ·Peter F.A. Mulders, Maria De Santis, Thomas Powles, Karim Fizazi	17
18	Rolle der Chemotherapie beim kastrationsresistenten Prostatakarzinom 2012 ·Der Urologe ·Maria De Santis, M. Bachner	0
19	Chemotherapie beim Prostatakarzinom 2008 ·Wiener klinische Wochenschrift ·Michael Rauchenwald, Maria De Santis, (unknown), W. Höltl, Gero Kramer, (unknown), (unknown), Andreas Reissigl, N. Schmeller, W. Stackl, Alfred Hobisch, Michael Krainer	1
20	Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study 2007 ·Annals of Oncology ·Karim Fizazi, Jan Oldenburg, Ariane Dunant, (unknown), Roberto Salvioni, Jakob Hartmann, Maria De Santis, Gedske Daugaard, (unknown), Ugo De Giorgi, Sergei Tjulandin, Hans‐Joachim Schmoll, J. Bouzy, Sophie D. Fosså, Gaëlle Fromont	61

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact